Estradiol Valerate
Injectable esterified form of 17-beta-estradiol, the principal human estrogen. Widely used in feminizing hormone therapy and menopausal HRT because the valerate ester slows release, giving stable estradiol levels from weekly or biweekly intramuscular or subcutaneous injection.
01 Overview
Estradiol valerate is a prodrug: the valerate ester is cleaved in circulation to release bioidentical 17-beta-estradiol. It is one of the most common injectable estrogens in transfeminine hormone therapy and is also used in menopausal replacement and, historically, in combined injectable contraceptives. Compared with oral estradiol it bypasses first-pass hepatic metabolism, which produces a smaller effect on hepatic clotting-factor synthesis at equivalent serum levels.
Dosing is individualised to a target serum estradiol range and monitored by blood levels rather than fixed by protocol. Supraphysiologic dosing raises thromboembolic and cardiovascular risk without improving feminization, so most clinicians titrate to physiologic female ranges.
02 Mechanism
The valerate ester hydrolyses to 17-beta-estradiol, which binds estrogen receptors alpha and beta, driving female secondary sex characteristics and, via negative feedback on the HPG axis, suppressing gonadotropins and endogenous testosterone.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Feminizing HRT | 2–10 mg/wk | IM | Titrated to serum estradiol ~100-200 pg/mL; often split biweekly. |
| Feminizing HRT (SC) | 2–10 mg/wk | SubQ | SC injection increasingly preferred; comparable levels to IM. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Breast developmentIrreversible glandular breast growth in transfeminine use; peak effect over years. | Tanner II-V over 2-3 yrs | Clinical | |
| Body fat redistributionShift toward gynoid (hip/thigh) fat pattern and softer skin over months. | Clinical | ||
| Testosterone suppressionNegative HPG feedback lowers endogenous testosterone, often reducing anti-androgen needs. | toward <50 ng/dL | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Venous thromboembolismIncreased risk of deep vein thrombosis and pulmonary embolism, rising with dose, age, smoking and thrombophilia. | Life-threatening | Uncommon but serious | Clinical | |
| Elevated prolactinEstrogen stimulates lactotrophs; marked persistent elevation warrants prolactinoma workup. | Mild | Common | Clinical | |
| Injection-site reactionLocal pain, redness or oil-related irritation from the sesame/castor oil vehicle. | Mild | Common | Observational |